José Manuel López-Suárez
Research Subjects
José Manuel López-Suárez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Ivanova
Max Weber Institute, Madrid
1 shared publicationArturo Rodríguez de la Serna
Hospital de la Santa Creu i Sant Pau, Barcelona
1 shared publicationBelén Aragón
MSD, Madrid, Spain
1 shared publicationCatalina Romo Guajardo-Fajardo
Primary Care Luis Taracido, Bollullos Par del Condado, Huelva, Spain
1 shared publication- David León Jiménez
Internal Medicine Department, Vascular Risk Unit, Hospital Universitario Virgen del Rocío, Seville, Spain (León-Jiménez)
1 shared publication E Rubio Romero
Rheumatology, HU Virgen del Rocio, Sevilla, Spain
1 shared publication
Latest Publications
- 1 December 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 158, 107916
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
- 1 December 2019
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 158, 107916
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 574-575
FRI0237 Safety of biosimilar infliximab use in a medical day hospital: a case-series
Background The first biosimilar anti-NTF (infliximab) approved by the EMA (European Medicines Agency) began to be used throughout Europe in 2015. Since then, it has been widely used throughout the world, even replacing the original treatment approved in 1999 Remicade® with Remsima®, a biosimilar drug. This medicine is currently approved to treat people who have been diagnosed with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis in the field of reheumatology, in addition to ulcerative colitis (UC) or Crohn's disease (EC) in gastroenterology. However, safety data of the use of Remsima® infliximab in a medical day hospital (MDH) are lacking. Objectives To report intrainfusion and postinfusion adverse events related to intravenous Remsima® use in a medical day hospital. Besides, we will describe the rehospitalizations and continuity of treatment in the follow up. Methods We designed a prospective uncontrolled case-series study. Patients referred from March 2015 to October 2016 to our MDH to receive intravenous Remsima® were consecutively enrolled. Demographic data were collected, and a harmonised active monitoring strategy was applied. We recorded the indication for treatment, the doses administered and the number and symptoms of acute transfusion reactions (ATR) occurring both in the infusion period and during the 3 hour postinfusion observation interval Results 2828 doses were administered, 0.67% presented ATR, all of them during the infusion and reported to the Regional Pharmacovigilance Center. 53% of those ATR were women and they were on average 35.78 years (SD 14.71). The mean dose used was 4,809 mg/kg (SD 0.47). The indications for treatment in patients suffering ATR were: EC (47%), CU (26%), Spondylitis (21%) and Psoriasis (5%). As a predominant symptom during ATR we found: shortness of breath (36.89%), pruritus (15.75%), flushing sensation (15.75%), urticaria (10.4%), alopecia (5.2%), chest pain (5.2%), paresthesia (5.2%) and nausea (5.2%). 95% of ATR showed complete recovery of the symptoms, 47% disappeared with the pause of infusion. However, they had prolonged in MDH stay, the infusion was stopped for 30 minutes and restarted at a lower rate according to the protocol. 21% of patients presenting ATR dropped out because of the symptomatology, which represents 0.14% of the total infusions. Conclusions Biosimilar Inflliximab seems to be safe in a MDH setting, given the low rate of adverse transfusion reactions during the 18 months analyzed. The most frequent adverse reaction was shortness of breath. Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 574-575
FRI0237 Safety of biosimilar infliximab use in a medical day hospital: a case-series
Background The first biosimilar anti-NTF (infliximab) approved by the EMA (European Medicines Agency) began to be used throughout Europe in 2015. Since then, it has been widely used throughout the world, even replacing the original treatment approved in 1999 Remicade® with Remsima®, a biosimilar drug. This medicine is currently approved to treat people who have been diagnosed with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis in the field of reheumatology, in addition to ulcerative colitis (UC) or Crohn's disease (EC) in gastroenterology. However, safety data of the use of Remsima® infliximab in a medical day hospital (MDH) are lacking. Objectives To report intrainfusion and postinfusion adverse events related to intravenous Remsima® use in a medical day hospital. Besides, we will describe the rehospitalizations and continuity of treatment in the follow up. Methods We designed a prospective uncontrolled case-series study. Patients referred from March 2015 to October 2016 to our MDH to receive intravenous Remsima® were consecutively enrolled. Demographic data were collected, and a harmonised active monitoring strategy was applied. We recorded the indication for treatment, the doses administered and the number and symptoms of acute transfusion reactions (ATR) occurring both in the infusion period and during the 3 hour postinfusion observation interval Results 2828 doses were administered, 0.67% presented ATR, all of them during the infusion and reported to the Regional Pharmacovigilance Center. 53% of those ATR were women and they were on average 35.78 years (SD 14.71). The mean dose used was 4,809 mg/kg (SD 0.47). The indications for treatment in patients suffering ATR were: EC (47%), CU (26%), Spondylitis (21%) and Psoriasis (5%). As a predominant symptom during ATR we found: shortness of breath (36.89%), pruritus (15.75%), flushing sensation (15.75%), urticaria (10.4%), alopecia (5.2%), chest pain (5.2%), paresthesia (5.2%) and nausea (5.2%). 95% of ATR showed complete recovery of the symptoms, 47% disappeared with the pause of infusion. However, they had prolonged in MDH stay, the infusion was stopped for 30 minutes and restarted at a lower rate according to the protocol. 21% of patients presenting ATR dropped out because of the symptomatology, which represents 0.14% of the total infusions. Conclusions Biosimilar Inflliximab seems to be safe in a MDH setting, given the low rate of adverse transfusion reactions during the 18 months analyzed. The most frequent adverse reaction was shortness of breath. Disclosure of Interest None declared
- Open Access
- 1 March 2017
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 13, 325-334
An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
Objective: To estimate the unit costs of administering intravenous (IV) biological agents in day hospitals (DHs) in the Spanish National Health System. Patients and methods: Data were obtained from 188 patients with rheumatoid arthritis, collected from nine DHs, receiving one of the following IV therapies: infliximab (n=48), rituximab (n=38), abatacept (n=41), or tocilizumab (n=61). The fieldwork was carried out between March 2013 and March 2014. The following three groups of costs were considered: 1) structural costs, 2) material costs, and 3) staff costs. Staff costs were considered a fixed cost and were estimated according to the DH theoretical level of activity, which includes, as well as personal care of each patient, the DH general activities (complete imputation method, CIM). In addition, an alternative calculation was performed, in which the staff costs were considered a variable cost imputed according to the time spent on direct care (partial imputation method, PIM). All costs were expressed in euros for the reference year 2014. Results: The average total cost was €146.12 per infusion (standard deviation [SD] ±87.11; CIM) and €29.70 per infusion (SD ±11.42; PIM). The structure-related costs per infusion varied between €2.23 and €62.35 per patient and DH; the cost of consumables oscillated between €3.48 and €20.34 per patient and DH. In terms of the care process, the average difference between the shortest and the longest time taken by different hospitals to administer an IV biological therapy was 113 minutes. Conclusion: The average total cost of infusion was less than that normally used in models of economic evaluation coming from secondary sources. This cost is even less when the staff costs are imputed according to the PIM. A high degree of variability was observed between different DHs in the cost of the consumables, in the structure-related costs, and in those of the care process.
- 1 March 2017
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 13, 325-334
Open AccessAn estimate of the cost of administering intravenous biological agents in Spanish day hospitals
Objective: To estimate the unit costs of administering intravenous (IV) biological agents in day hospitals (DHs) in the Spanish National Health System. Patients and methods: Data were obtained from 188 patients with rheumatoid arthritis, collected from nine DHs, receiving one of the following IV therapies: infliximab (n=48), rituximab (n=38), abatacept (n=41), or tocilizumab (n=61). The fieldwork was carried out between March 2013 and March 2014. The following three groups of costs were considered: 1) structural costs, 2) material costs, and 3) staff costs. Staff costs were considered a fixed cost and were estimated according to the DH theoretical level of activity, which includes, as well as personal care of each patient, the DH general activities (complete imputation method, CIM). In addition, an alternative calculation was performed, in which the staff costs were considered a variable cost imputed according to the time spent on direct care (partial imputation method, PIM). All costs were expressed in euros for the reference year 2014. Results: The average total cost was €146.12 per infusion (standard deviation [SD] ±87.11; CIM) and €29.70 per infusion (SD ±11.42; PIM). The structure-related costs per infusion varied between €2.23 and €62.35 per patient and DH; the cost of consumables oscillated between €3.48 and €20.34 per patient and DH. In terms of the care process, the average difference between the shortest and the longest time taken by different hospitals to administer an IV biological therapy was 113 minutes. Conclusion: The average total cost of infusion was less than that normally used in models of economic evaluation coming from secondary sources. This cost is even less when the staff costs are imputed according to the PIM. A high degree of variability was observed between different DHs in the cost of the consumables, in the structure-related costs, and in those of the care process.